Outcomes of First-Line Pembrolizumab Monotherapy for PD-L1–positive (TPS ≥50%) Metastatic NSCLC at US Oncology Practices
Video journal of biomedicine(2020)
Abstract
In this Publication Perspective, lead author Vamsidhar Velcheti, New York University, provides a summary of article 'Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices' published in Immunotherapy that looks at real-world outcomes with first-line pembrolizumab monotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor expression ≥50%.
MoreTranslated text
Key words
antineoplastic agents,comparative effectiveness research,non-small-cell lung carcinoma,pembrolizumab,PD-L1,survival analysis
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined